Dong Wook Kim
Garam Mental Health Clinic · Eulji University · the Catholic University of Korea's St. Mary's Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Dong Wook Kim as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:22 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07834112 · Body Weight Changes After Switching to Lurasidone for Antipsychotic-induced Weight Gain in Bipolar DisorderDong-Wook Kim · completed · Bipolar Disorder (BD) · study chair
- N/ANCT06945146 · Genomics Study in CML Patients With Ponatinib TreatmentDong-Wook Kim · completed · Chronic Myelogenous Leukemia, BCR-ABL1 Positive · principal investigator
- Ph3NCT03459534 · A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIsIl-Yang Pharm. Co., Ltd. · recruiting · Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory · principal investigator
- N/ANCT02034656 · Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA)Seoul St. Mary's Hospital · unknown · Chronic Myeloid Leukemia or Ph Positive ALL · principal investigator
- N/ANCT01562847 · Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With NilotinibSeoul St. Mary's Hospital · unknown · Chronic Myeloid Leukemia · principal investigator
- Ph3NCT01400074 · Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to ImatinibSeoul St. Mary's Hospital · unknown · Chronic Myeloid Leukemia · principal investigator
- Ph2NCT01216085 · An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular EndpointsNovartis Pharmaceuticals · completed · CML, Imatinib · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 28 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in chronic myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 11:22 UTC. The ranking covers the 200 most relevant of 73 PubMed records, and a shared surname and initials can bring in a namesake. All 73 on PubMed
- Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.N Engl J Med · 20101,328 citationsRCR 30.4
- A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.N Engl J Med · 2013903 citationsRCR 24.7
- 648 citationsRCR 22.0
- 492 citationsRCR 18.4
- 471 citationsRCR 12.6
- 402 citationsRCR 8.2
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.N Engl J Med · 2019376 citationsRCR 13.6
- 374 citationsRCR 9.2
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.J Clin Oncol · 2018366 citationsRCR 12.8
- Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.J Clin Oncol · 2012352 citationsRCR 9.8